Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

uniQure paring down gene therapy portfolio

Chris Lieu
November 15, 2016 11:50 PM UTC

Gene therapy company uniQure N.V. (NASDAQ:QURE) said it will reduce headcount by 20-25%, eliminating 50-60 positions by YE17, in order to focus on key pipeline projects.

The company expects the job cuts will save EUR 5-6 million ($5.4-$6.4 million) annually, while reprioritizing the pipeline will reduce expenses by EUR 11-15 million ($11.8-$16.1 million) over two years...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Bristol Myers Squibb Co.

Uniqure N.V.